title: Acute hepatitis C in a patient receiving etanercept.
abstract: According to the literature, the use of tumor necrosis factor (TNF) inhibitors in patients with chronic hepatitis C infection is safe and effective. There have been no reports, however, of primary infection with the hepatitis C virus during treatment with a biologic agent. We report the case of a patient with long-standing moderate to severe psoriasis who developed acute hepatitis C while being treated with etanercept. Biologic therapy was continued and the infection was successfully treated with pegylated interferon, which achieved a sustained virologic response. Etanercept did not have a negative impact on disease outcome or on response to antiviral treatment.
authors.affiliation: Servicio de Dermatología, Hospital Arnau de Vilanova, Valencia, Spain. miquelarmengot@gmail.com
authors.forename: M
authors.initials: M
authors.lastname: Armengot-Carbó
authors.forename: M
authors.initials: M
authors.lastname: Velasco
authors.forename: R
authors.initials: R
authors.lastname: Giner
authors.forename: E
authors.initials: E
authors.lastname: Gimeno
mesh_terms: D000208:Acute Disease; D000068800:Etanercept; D006526:Hepatitis C / Q000139:chemically induced*; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D018124:Receptors, Tumor Necrosis Factor / Q000037:antagonists & inhibitors*
chemical_list: D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000068800:Etanercept